Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

Tisotumab vedotin (Tivdak, Genmab) is indicated for 'the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy'.

The dosage schedule is available in the summary of product characteristics for tisotumab vedotin.

The list price for tisotumab vedotin is £1,995 per 40 mg powder vial (company submission addendum).

The company has a commercial arrangement. This makes tisotumab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, Genmab did not disclose its Carbon Reduction Plan for UK carbon emissions.